Kornimate/medical-research-clean huggingface dataset:
endovascular procedures with computer assistance in the chronic occlusive arthritis of the lower limbs on the femoro-popliteal stage.

Conditions: Peripheral Arterial Disease

Summary: pilot study to assess the feasibility of creation of a bone and arterial panorama by 2d-2d registration technique during endovascular femoro-popliteal procedures with a mobile c-arm x-ray system using endonaut® software.

the aim of this study is to show that it is possible to give a complete image of the area to be operated by the surgeon by creating a complete bone and arterial panorama of the femoro-popliteal axis with 2d-2d registration techniques. this study should have a clinical impact for the patient and caregiver. with this technique, we expect a reduction in the irradiation of the patient and the caregivers, a decrease in the volume of injected contrast product and a decrease in operating time.

Eligibility criteria:
inclusion criteria: * patients with peripheral arterial disease of the lower limbs, all clinical stages, lesions of the femoro-popliteal stage and candidates for endovascular treatment of these lesions. * major patients * patients not opposed to their participation in the study exclusion criteria: * patients requiring conventional surgical revascularization. * patient under legal protection (guardianship, safeguard of justice). * pregnant or lactating women

Keywords: occlusive arthritis bone panorama arterial panorama
study of the braive growth modulation system for progressive pediatric scoliosis

Conditions: Juvenile Idiopathic Scoliosis; Adolescent Idiopathic Scoliosis

Summary: the purpose of this study was to establish probable benefits and evaluate the safety and preliminary effectiveness of the braive™ gms when used in the treatment of pediatric progressive scoliosis.


Eligibility criteria:
inclusion criteria: a subject must meet all of the following inclusion criteria to participate in this study: * has a diagnosis of juvenile or adolescent idiopathic scoliosis * is skeletally immature with a sanders score of ≥2 to ≤5 * has failed conservative care as per investigator's assessment * has a main thoracic cobb angle between 30 and 60 degrees * has a lenke classification of 1a, 1b, or 1c * has kyphosis ≤ 40 degrees with a sagittal thoracic modifier n or negative * informed consent form/assent and authorization to use and disclose health information (if applicable) have been signed by parent/legal guardian and/or patient/participant per local requirement. exclusion criteria: a subject will be excluded from participating in this study for any of the following reasons: * has undergone previous spinal fusion procedure(s) at the affected levels * is pregnant or plans to become pregnant within the first 24-months of the study * has a curve that requires instrumentation below l1 * has spinal mri abnormalities (e.g., chiari malformation, syrinx greater than 4mm, tethered cord) * has any type of non-idiopathic scoliosis * has a left-sided curve * has an associated syndrome * has a history of malignant hyperthermia * has an active or significant risk of infection (immunocompromised) * has inadequate tissue coverage over the operative site as per investigator's assessment * has a suspected or documented allergy or intolerance to implant materials * has a major psychiatric disorder / history of drug abuse that would interfere with the subject's ability to comply with study instructions or might confound the study interpretation as per investigator's assessment (dsm-5 can be used as a reference) * is a ward of the court/state * has had prior ipsilateral or contralateral chest surgery * has severe chronic lung disease (e.g., asthma, bronchiectasis) * has poor bone quality, as determined by the investigator, that may limit anterior fixation * is unwilling or unable to return for follow-up visits and/or follow intra-operative and/or postoperative instructions * concurrent participation in another clinical study that may add additional safety risks and/or confound study results

Keywords: juvenile idiopathic scoliosis adolescent idiopathic scoliosis progressive scoliosis braive anterior vertebral body tethering avbt growth modulation system
pharmacokinetic analysis of posaconazole in lung transplant recipients

Conditions: Lung Transplant Infection; Fungal Infection

Summary: this is a single center, observational study of posaconazole pk sampling in lung transplant recipients. the patients enrolled will have up to 6 (3ml) pk samples (a total of 18 ml) and one 10ml blood sample for a total collection of 28ml of blood obtained over the entire study. in addition, the investigators will collect medical record information and any excess bal samples available during the study (tests done as part of the patient's clinical care and the samples would have been discarded once diagnosis was made).

pk blood samples will be obtained around a clinical dosing of posaconazole

Eligibility criteria:
inclusion criteria: * 18 years of age and older receiving posaconazole post transplant as part of their care received a lung transplant exclusion criteria: * must meet inclusion criteria

Keywords: posaconazole pk blood sampling
optical coherence tomography in stemi

Conditions: STEMI

Summary: the overall objective of this research proposal is to use oct to investigate those morphological culprit plaque characteristics associated with the risk of developing mvo in reperfused stemi patients.

the specific research objectives include: 1. to use oct to determine the type of plaque (plaque rupture, plaque erosion or calcified nodule) most associated with the presence and severity of mvo (as measured by imr and cardiac mri). 2. to use oct to investigate the relationship between the extent of tissue protrusion and the amount of residual stent thrombus with the presence and severity of mvo (as measured by imr and cardiac mri).

Eligibility criteria:
inclusion criteria: 1. confirmed stemi as per the in-charge consultant based on presenting history, ecg and angiogram findings. 2. \< 12 hours of onset of chest pain. 3. ability to provide informed consent exclusion criteria: 1. previous myocardial infarction or coronary artery bypass graft surgery 2. cardiac arrest or cardiogenic shock 3. inability to advance the oct catheter or to obtain good image quality 4. ostial lesions 5. significant renal impairment 6. contraindications for cardiac mri 7. contraindication for adenosine (for imr measurement)
autologous cell suspension grafting using recell in vitiligo and piebaldism patients

Conditions: Piebaldism; Segmental Vitiligo

Summary: autologous epidermal cell suspension grafting is an effective method of surgical treatment in vitiligo, which is suitable for treating larger areas with better cosmetic results as compared to other grafting methods. the recell autologous cell harvesting device (avita medical europe limited, cambridge, uk) is an autologous cell harvesting device which, compared to other forms of autologous epidermal cell suspension grafting, is easier in use showing similar results. furthermore, the recell device needs no laboratory facilities. therefore, it is promising for patients with large vitiligo and piebaldism lesions. objectives: primary: to asses the efficacy and safety of autologous epidermal cell suspension grafting with the recell device after co2 laser abrasion compared to co2 laser abrasion alone and no treatment, in patients with piebaldism and stable vitiligo. secondary: to assess the practical aspects and patients satisfaction of autologous epidermal cell suspension grafting with the recell device. study design: prospective observer blinded randomized controlled pilot study. study population: 10 patients ≥ 18 years with stable segmental vitiligo or piebaldism who are under treatment at the netherlands institute for pigment disorders (nipd) at the academic medical centre university of amsterdam. methods: three depigmented regions on the trunk or proximal extremities will be randomly allocated to; co2 laser abrasion + recell autologous cell suspension grafting, or co2 laser abrasion, or no treatment. after the transplantation, uv-treatment according to the standard treatment protocol of the nipd will be started on all sites and continued for 3 months. three and six months after grafting, the percentage of repigmentation of the lesions will be assessed.


Eligibility criteria:
inclusion criteria: * patient with piebaldism * patients with segmental vitiligo,stable since 12 months without systemic therapy or topical therapy as defined by the absence of new lesions and/or enlargement of existing lesions * with at least three depigmented skin lesions on the proximal extremities or trunk larger than 3x3 cm or one lesion of at least 9x3 cm * age \>18 * willing and able to give written informed consent exclusion criteria: * uv therapy or systemic immunosuppressive treatment during the last 12 months * local treatment of vitiligo during the last 12 months * vitiligo lesions with follicular or non-follicular repigmentation * skin type i * recurrent hsv skin infections * hypertrophic scars * keloid * cardial insufficiency * patients with a history of hypersensitivity to (uvb or uva) light and/or allergy to local anesthesia. * patients who are pregnant or breast-feeding * patients not competent to understand the procedures involved * patients with atypical nevi * patients with a personal history of melanoma or non-melanoma skin cancer
utilizing electronic clinical decision support to enhance mtbi care at the primary care point of entry

Conditions: Brain Concussion; Mild Traumatic Brain Injury

Summary: six primary care practices within a large philadelphia pediatric care network will use an electronic clinical decision support (ecds) tool as standard care for concussion evaluation. the ecds tool will include a prediction rule for children aged 5-18 assessed for mild traumatic brain injury (mtbi). the ecds tool predicts risk for persistent symptoms and prompts referral to specialty care for those deemed high risk. this research proposes to analyze the clinical and process outcomes in these six practices relative to the rest of the care network, specifically, whether the ecds tool reduces time to symptom resolution.

the electronic clinical decision support tool will include a prediction rule for children aged 5-18 assessed for mild traumatic brain injury (mtbi). it predicts risk for persistent symptoms and prompts referral to specialty care for those who are high-risk. the ecds tool consists of a validated, age-appropriate symptom scale, risk stratification with indication for specialty referral, personalized return to activity guidance based on symptom exacerbation, and guidance on minimizing prolonged rest and promoting active management. each year for three years, the ecds tool will go live at a new pair of sites (1 urban, 1 suburban). training will be provided to the primary care providers at these sites on utilizing the ecds tool. anonymous questionnaires will be administered among providers who used the ecds tool in order to evaluate its appropriateness and acceptability. a medical record review will be conducted of mtbi patients evaluated with the ecds tool.

Eligibility criteria:
inclusion criteria: * 5-18 year old patients evaluated for mild traumatic brain injury at a children's hospital of philadelphia primary care practice within the study timeframe exclusion criteria: * evidence of moderate or severe tbi

Keywords: clinical decision support persisting post-concussion symptoms
doppler-guided endoscopic treatment in peptic ulcer bleeding

Conditions: Peptic Ulcer Bleeding

Summary: the present study is a randomized controlled trial (rct) that examines if the outcome of peptic ulcer bleeding could be improved by use of doppler-guided endoscopic treatment.

this study evaluates if performance of a control endoscopy with doppler-guided endoscopic treatment is associated with an improved outcome in term of lower rate of rebleeding and lower rate of bleeding-related mortality. a potential risk of increased risk of complications (in particular perforation) among patients treated with control endoscopy is also evaluated. outcomes are prospectively registered based on patient records.

Eligibility criteria:
inclusion criteria: * peptic ulcer bleeding from ulcers classified as forrest i-iib exclusion criteria: * severe comorbidity with a remaining life expectancy below 30 days
early recovery after cesarean delivery - maternal glucose homeostasis following preoperative glucose dose

Conditions: Gestational Diabetes; Cesarean Section Complications

Summary: diabetic parturients planned for cesarean delivery will be recruited for the study. they will receive a fixed glucose dose to mimize the effects of fasting preoperatively and their blood glucose levels will be monitored.

informed voluntary parturients planned for cesarean delivery will be informed about the study. the parturients will get prepacked glucose drink containing 100 g and 50 g glucose, respectively. they will consume the 100 g of glucose the night before the planned operation and the 50 g on the morning of the planned cesarean delivery. their blood glucose level will be monitored by percutaneous continuous blood glucose monitoring every 30 minutes for 2 hours following the glucose dose in the evening and for four hours in the morning of the operation. the subjective well being of these parturients will be also qualitatively assessed.

Eligibility criteria:
inclusion criteria: * volunteers to participate in the study * diabetes, either gestational or type ii * planned for cesarean delivery exclusion criteria: * type i diabetes
smartphone app for analysis of general movements in young infants

Conditions: Cerebral Palsy

Summary: analysis of spontaneous movements in young infants from video recordings is recommended as an early medical assessment tool for prediction of cerebral palsy in high-risk infants. such video recording have previously been performed in follow-up programs at hospitals using semi standardized video set-ups. the research group behind this study develops a smart-phone application that makes it possible for parents to video film their infant spontaneous movements at home, upload and send the video for analysis at the hospital provided by experts. the objectives of the study are to assess the feasibility of the in-motion app for video recording of infant spontaneous movements, upload and send the video to st. olavs hospital in trondheim, norway, for assessment, and how parents experience this. 90-120 high-risk infants from norway, denmark, belgium, usa, great britain and india will participate. parents will record their infant spontaneous movements and answer questionnaires. video quality will be evaluated by experts within the field and their use for computer-based assessment will be evaluated.


Eligibility criteria:
inclusion criteria: * infants referred to high-risk follow-up at the hospital exclusion criteria: * unstable medical condition, progressive disorders, or diagnosis with a specific syndrome affecting motor development.

Keywords: infants, newborn general movements video recording mobile applications prognosis parents
systematic screening with electrocardiogram for unknown atrial fibrillation in 65 years old and above people in nursing home

Conditions: Atrial Fibrillation

Summary: atrial fibrillation is the most common arrhythmia. some studies shown that systematic screening with electrocardiogram could improve atrial fibrillation detection. no studies are available in nursing home. the goal of this study is to screen atrial fibrillation in patients who live in nursing home.

a prospective observational cross sectional multicenter study. the goal of this study is to detect atrial fibrillation in nursing home people aged 65 years old and above, with systematic electrocardiogram. participants agreement will be collected. participants characteristics data will be collected in all nursing home. for all participants, one visit were realised with electrocardiogram, and symptoms survey. data were anonymised on each center before analysed.

Eligibility criteria:
inclusion criteria : * being in nursing home since 1 month and above * aged \> 65 years old * subjects agree to participate at this project exclusion criteria : * antecedent of atrial fibrillation
nutritional deficiency and recurrent miscarriage

Conditions: Recurrent Miscarriage

Summary: this prospective cohort study primarily aims to examine the association between blood niacin levels and recurrent miscarriage.

recurrent miscarriage is affecting around 5% women at reproductive age. and the underlying causes remain undetermined in 50%-70% of cases. although animal models and linkage analysis according to family studies have identified that niacin deficiency can lead to congenital malformations and recurrent miscarriage. evidence based on population is lacking with regard to the effect of blood niacin levels on recurrent miscarriage. we intend to enroll 499 pregnant women confirmed by a positive blood human chorionic gonadotropin test and with history of unexplained recurrent miscarriage. by testing their blood niacin levels and following up to the end of first-trimester pregnancy, this study aims to examine the role of niacin levels in preventing miscarriages among women with history of recurrent miscarriage.

Eligibility criteria:
inclusion criteria: * 18-40years old, female * positive blood human chorionic gonadotropin test * naturally pregnant * history of recurrent miscarriage (2 or more consecutive spontaneous miscarriage within 28 weeks of gestation) * willing to participate in this study with informed consent exclusion criteria: * women whose confirmed cause of recurrent miscarriage has nothing to do with nutritional deficiencies, including chromosomal abnormalities, abnormal uterine anatomy, immune system diseases, blood diseases, etc. * women with hepatitis b, syphilis, hiv/aids and other infectious diseases. * women with serious conditions, such as schizophrenia, tumors, heart failure
national referral center study of transthyretin amyloid cardiomyopathy(attr) patients on tafamidis

Conditions: Amyloidosis; Amyloidosis Cardiac; ATTR Amyloidosis Wild Type

Summary: all attrwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to italian medicines agency regulations. c onsidering the significant risk of developing heart rhythm disturbances due to cardiac amyloidosis, especially in transthyretin form (attrwt), in routine clinical practice a stricter heart rhythm monitoring is recommended in attrwt patients. moreover, particular attention is usually paid for those who present atrio-ventricular and/or intraventricular block at the baseline electrocardiogram. data about rhythm disturbances and diuretic dose need will be collected during the planned physical examination every six months and the holter ecg monitoring requested by the physician at the end of every planned clinical evaluation.


Eligibility criteria:
inclusion criteria: * diagnosis of attrwt amyloidosis. * 18 years or older; * evidence of cardiac involvement at echocardiography or cardiac mri. * no known prior history of atrial fibrillation or major bradyarrhythmia (second degree atrioventricular block, third-degree atrioventricular block, high-grade atrioventricular block or alternating right and left branch block) * female patients who are postmenopausal for at least 1 year before the screening visit * patients on therapy or candidates for therapy with tafamidis 61 mg * voluntary written consent must be given before performance of any study-related procedure not part of standard medical care with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care. exclusion criteria: * non-attr amyloidosis; * nyha class iii and iv; * pregnant or nursing women; * previous pacemaker implantation; * any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with a fully comprehension of the written consent form
evaluation of 89zr-tlx250 pet/ct in chinese patients with indeterminate renal masses or suspected recurrent renal clear cell carcinoma

Conditions: Clear Cell Renal Cell Carcinoma; Suspected Recurrent Renal Clear Cell Carcinoma; Recurrent Renal Cell Cancer

Summary: the study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89zr-tlx250 (also known as 89zr-dfo-girentuximab) positron emission tomography/computed tomography (pet/ct) in adult chinese patients with indeterminate renal masses or suspected recurrent renal clear cell carcinoma


Eligibility criteria:
inclusion criteria: 1. voluntarily signed written informed consent 2. chinese male or female≥18 years old. 3. have an indeterminate renal mass, suspected renal cell carcinoma, or previously diagnosed ccrcc, suspected recurrence on the pre-screening imaging from day -90 to day -1 4. negative serum pregnancy test for female subjects of childbearing potential at screening. confirmed negative urine pregnancy test within 24 hours prior to administration of investigational product. 5. expected survival ≥ 6 months. 6. agree to follow appropriate and highly effective contraception method for at least 35 days after the administration of 89zr-tlx250. exclusion criteria: 1. renal mass is known to be a metastasis of another primary tumor. 2. have other malignancies that require treatment. 3. planned antineoplastic therapies (for the period between iv administration of 89zr-tlx250 and imaging). 4. have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the planned administration of 89zr-tlx250 or such therapy resulted in a persistent adverse event (\> grade 1) (per national cancer institute-common toxicity criteria version 5.0 \[ncictcae v5.0\]). 5. exposure to murine or chimeric antibodies within the last 5 years. 6. prior use of radionuclides with an interval of less than 10 halflives. 7. exposure to any investigational diagnostic or therapeutic agent within the first 4 weeks or 5 half-lives (whichever is longer) of the planned administration of 89zr-tlx250. 8. renal insufficiency with glomerular filtration rate (gfr) ≤ 60 ml/min/1.73 m². 9. uncontrolled psychiatric disorders. 10. women who are pregnant or breastfeeding. 11. known hypersensitivity to girentuximab or dfo (deferoxamine). 12. have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease) that, in the opinion of the investigator, may interfere with the purpose of the study or subject safety or compliance. 13. vulnerable population (e.g., being in detention).

Keywords: indeterminate renal masses suspected recurrent renal clear cell carcinoma